Original Publication Date: 1 November, 2016
Publication / Source: Epigenomics
Authors: Pei Liu, Jacson K Shen, Jianzhong Xu, Carol A Trahan, Francis J Hornicek & Zhenfeng Duan
Chondrosarcoma (CS) is the second most common primary malignant bone tumor. Unlike other bone tumors, CS is highly resistant to conventional chemotherapy and radiotherapy, thus resulting in poor patient outcomes. There is an urgent need to establish alternative therapies for CS. However, the etiology and pathogenesis of CS still remain elusive. Recently, DNA methylation-associated epigenetic changes have been found to play a pivotal role in the initiation and development of human cancers, including CS, by regulating target gene expression in different cellular pathways.